AIM ImmunoTech Inc. CEO and President Thomas K. Equels filed a Form 4 with the SEC on November 6, 2026, disclosing a direct open-market purchase of common stock in the company.

Key Highlights

  • Reporting person: Thomas K. Equels, identified in the filing as Director, CEO, and President of AIM ImmunoTech Inc.
  • Transaction: Purchase (transaction code P) of 20,299 shares of common stock on November 6, 2026.
  • Price paid: $0.156 per share, according to the filing.
  • Resulting ownership: Following the transaction, Equels directly beneficially owned 210,046 shares of common stock.
  • Ownership form: All shares reported as directly held.
  • No derivative transactions were reported in Table II of the filing.

Equels Adds to Direct Common Stock Position in November 2026 Transaction

According to the Form 4 filed with the SEC, Thomas K. Equels, who serves as Director, CEO, and President of AIM ImmunoTech Inc. (NASDAQ:AIM), acquired 20,299 shares of the company's common stock on November 6, 2026. The transaction was recorded under transaction code P, indicating a purchase. The price reported for the acquisition was $0.156 per share.

Following the reported transaction, the filing states that Equels held a total of 210,046 shares of AIM ImmunoTech common stock, all classified as directly owned. No deemed execution date was listed for the transaction, and the filing was made by one reporting person. The form was signed by Thomas K. Equels and dated November 6, 2026.

Table II of the filing, which covers derivative securities such as options, warrants, or convertible securities, contained no reported transactions or positions. The filing does not include any explanation of responses or footnotes beyond the standard form disclosures.

What Was Disclosed

The filing disclosed a single open-market purchase of 20,299 shares of AIM ImmunoTech common stock at $0.156 per share by CEO and President Thomas K. Equels on November 6, 2026, bringing his direct beneficial ownership to 210,046 shares.